Health Condition 1: C56- Malignant neoplasm of ovary Health Condition 2: C61- Malignant neoplasm of prostate Health Condition 3: C50-C50- Malignant neoplasms of breast
Conditions
Interventions
None listed
Sponsors
Strand Life Sciences Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with confirmed malignant carcinoma of the breast, ovary and prostate who are eligible for PARP inhibitor therapy and will be undergoing PARP inhibitor therapy as identified by the site Principal Investigator or co-Investigators through routine clinical care processes 2. Age - 18 years and above 3. Both men and women of all races and ethnic groups are eligible for this study 4. New, relapsed, recurrent cases 5. Ability to understand and the willingness to sign a written Informed Consent Form
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women 2. Patients who have an uncontrolled infection 3. Patients who are receiving any additional oncology investigational agent(s) with PARP inhibitors 4. Patients who are coagulopathic and are taking blood thinning products
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of signature biomarkers via a minimally invasive procedure will enable distinguishing between PARP inhibitor responder and non-responder or patient prognosis while on PARP inhibitor therapy.Timepoint: Outcome will be assessed at the end of the therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| To identify molecular signature determining sensitivity to these inhibitorsTimepoint: Outcome will be assessed at the end of the therapy | — |
Countries
India
Contacts
Public ContactDr Vamsi Veeramachaneni
Strand Life Sciences Pvt Ltd
Outcome results
None listed